Cabaletta Bio Inc (NASDAQ: CABA) has experienced a rise in its stock price by 12.76 compared to its previous closing price of 2.43. However, the company has seen a gain of 32.05% in its stock price over the last five trading days. seekingalpha.com reported 2025-01-06 that Cabaletta Bio, Inc.’s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has enough cash to operate for 5–6 quarters, assuming no further expense growth or additional financing. Risks include the aggressive nature of CAR T-cell therapy for non-life-threatening diseases and competition from other cell therapy approaches.
Is It Worth Investing in Cabaletta Bio Inc (NASDAQ: CABA) Right Now?
Moreover, the 36-month beta value for CABA is 2.47. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CABA is 41.37M and currently, short sellers hold a 14.55% of that float. On January 20, 2025, CABA’s average trading volume was 2.50M shares.
CABA’s Market Performance
CABA stock saw an increase of 32.05% in the past week, with a monthly gain of 1.11% and a quarterly increase of -41.20%. The volatility ratio for the week is 11.87%, and the volatility levels for the last 30 days are 11.46% for Cabaletta Bio Inc (CABA). The simple moving average for the past 20 days is 16.14% for CABA’s stock, with a -59.71% simple moving average for the past 200 days.
Analysts’ Opinion of CABA
Many brokerage firms have already submitted their reports for CABA stocks, with Evercore ISI repeating the rating for CABA by listing it as a “In-line.” The predicted price for CABA in the upcoming period, according to Evercore ISI is $6 based on the research report published on December 20, 2024 of the previous year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see CABA reach a price target of $6, previously predicting the price at $12. The rating they have provided for CABA stocks is “Equal Weight” according to the report published on December 19th, 2024.
UBS gave a rating of “Buy” to CABA, setting the target price at $10 in the report published on October 10th of the previous year.
CABA Trading at -5.82% from the 50-Day Moving Average
After a stumble in the market that brought CABA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.60% of loss for the given period.
Volatility was left at 11.46%, however, over the last 30 days, the volatility rate increased by 11.87%, as shares sank -0.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.50% lower at present.
During the last 5 trading sessions, CABA rose by +32.05%, which changed the moving average for the period of 200-days by -83.38% in comparison to the 20-day moving average, which settled at $2.36. In addition, Cabaletta Bio Inc saw 20.70% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CABA
Current profitability levels for the company are sitting at:
- -28.55 for the present operating margin
- 0.71 for the gross margin
The net margin for Cabaletta Bio Inc stands at -25.98. The total capital return value is set at -0.63. Equity return is now at value -62.16, with -55.16 for asset returns.
Based on Cabaletta Bio Inc (CABA), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -5.36. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -103.9.
Currently, EBITDA for the company is -73.23 million with net debt to EBITDA at 1.38. When we switch over and look at the enterprise to sales, we see a ratio of -5.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.11.
Conclusion
To wrap up, the performance of Cabaletta Bio Inc (CABA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
